CareDx, Inc (NASDAQ:CDNA – Get Rating) insider Reginald Seeto offered 2,818 shares of the corporate’s inventory in a transaction dated Tuesday, January third. The shares have been offered at a median worth of $11.69, for a complete worth of $32,942.42. Following the completion of the sale, the insider now straight owns 268,906 shares of the corporate’s inventory, valued at $3,143,511.14. The sale was disclosed in a submitting with the SEC, which will be accessed by means of the SEC website.
CareDx Inventory Efficiency
NASDAQ:CDNA traded down $0.31 throughout mid-day buying and selling on Tuesday, reaching $11.10. The inventory had a buying and selling quantity of 1,016,432 shares, in comparison with its common quantity of 1,058,282. CareDx, Inc has a twelve month low of $10.68 and a twelve month excessive of $47.82. The enterprise has a 50 day easy transferring common of $13.89 and a 200 day easy transferring common of $18.34. The agency has a market capitalization of $594.26 million, a price-to-earnings ratio of -7.87 and a beta of 0.92.
Institutional Buying and selling of CareDx
A lot of institutional buyers have just lately modified their holdings of CDNA. Rockefeller Capital Administration L.P. grew its place in CareDx by 272.4% throughout the third quarter. Rockefeller Capital Administration L.P. now owns 4,108 shares of the corporate’s inventory value $69,000 after shopping for an extra 3,005 shares throughout the interval. Grandeur Peak World Advisors LLC acquired a brand new place in shares of CareDx throughout the 1st quarter value roughly $87,000. Lazard Asset Administration LLC grew its holdings in CareDx by 64.0% throughout the 2nd quarter. Lazard Asset Administration LLC now owns 5,290 shares of the corporate’s inventory valued at $113,000 after shopping for an extra 2,065 shares over the last quarter. Shell Asset Administration Co. elevated its place in CareDx by 152.9% throughout the second quarter. Shell Asset Administration Co. now owns 5,953 shares of the corporate’s inventory value $128,000 after shopping for an extra 3,599 shares within the final quarter. Lastly, Point72 Hong Kong Ltd acquired a brand new place in shares of CareDx within the first quarter value $131,000.
Analysts Set New Value Targets
A number of analysis corporations have just lately weighed in on CDNA. Raymond James decreased their worth goal on CareDx from $35.00 to $26.00 and set a “strong-buy” score for the corporate in a report on Monday, November seventh. BTIG Analysis dropped their worth goal on shares of CareDx from $37.00 to $28.00 and set a “purchase” score on the inventory in a analysis be aware on Monday, November seventh. The Goldman Sachs Group lowered their worth goal on CareDx from $45.00 to $40.00 and set a “purchase” score on the inventory in a report on Friday, November 4th. Lastly, StockNews.com raised CareDx from a “promote” score to a “maintain” score in a analysis be aware on Friday, November 4th. One analyst has rated the inventory with a maintain score, three have given a purchase score and one has issued a powerful purchase score to the inventory. In accordance with information from MarketBeat, CareDx has a median score of “Purchase” and a consensus goal worth of $46.20.
CareDx Firm Profile
CareDx, Inc discovers, develops, and commercializes diagnostic options for transplant sufferers and caregivers worldwide. It gives AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) answer for kidney transplant sufferers; AlloMap Coronary heart, a gene expression answer for coronary heart transplant sufferers; AlloSure Coronary heart, a dd-cfDNA answer for coronary heart transplant sufferers; and AlloSure Lung, a dd-cfDNA answer for lung transplant sufferers.
This instantaneous information alert was generated by narrative science expertise and monetary information from MarketBeat with the intention to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial crew previous to publication. Please ship any questions or feedback about this story to email@example.com.
Earlier than you take into account CareDx, you will need to hear this.
MarketBeat retains monitor of Wall Road’s top-rated and finest performing analysis analysts and the shares they advocate to their purchasers every day. MarketBeat has recognized the five stocks that prime analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and CareDx wasn’t on the checklist.
Whereas CareDx presently has a “Purchase” score amongst analysts, top-rated analysts consider these 5 shares are higher buys.